Over $50 Billion Blockbuster Anticoagulant Faces New Competition as Hengrui, China Resources, Bayer Enter the Arena
Oct 07, 2023 11:43
CST Updated
11:43
Hengrui Pharma
Innovative and High-Quality Pharmaceutical Developer
CR PHARMA COMM
Pharmaceutical Circulation Service Provider
Salubris
Pharmaceutical Product R&D Developer
Bristol-Myers Squibb
Biopharmaceutical and Nutritional Product R&D and Sales
MSD
Pharmaceutical R&D and Manufacturer
Bayer
Pharmaceutical Product R&D Developer
Regeneron
Biopharmaceutical Manufacturer
Anthos Therapeutics
Antibody Drug Developer
Abelacimab significantly reduces the incidence of bleeding, marking an important breakthrough in the safety of anticoagulants. The peak market size in China exceeds 44 billion yuan. The "Report on Cardiovascular Health and Diseases in China 2022" shows that the prevalence of cardiovascular diseases in China is in a continuous upward trend.